Genomic Health, Inc. Sustainability Profile
Genomic Health, Inc., a leader in precision medicine, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2000, the company has made significant strides in the field of genomic testing, particularly in oncology, with its innovative assays that help guide treatment decisions for cancer patients. The company’s flagship products, including the Oncotype DX® test, are designed to assess the likelihood of cancer recurrence and the potential benefit of chemotherapy, setting them apart in the personalised medicine landscape. Genomic Health has established a strong market position, recognised for its commitment to improving patient outcomes through advanced genomic insights. With numerous accolades and a robust portfolio, Genomic Health continues to shape the future of cancer care.
DitchCarbon Score
How does Genomic Health, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genomic Health, Inc.'s score of 41 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genomic Health, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is a current subsidiary of Exact Sciences Corporation, which may influence its climate commitments and emissions reporting. As part of its corporate family, Genomic Health inherits climate initiatives and targets from Exact Sciences Corporation. However, there are no documented reduction targets or significant climate pledges specifically attributed to Genomic Health at this time. The absence of specific emissions data and reduction initiatives suggests that the company may still be in the process of establishing its own climate strategy or reporting framework. In the context of the broader industry, it is essential for companies like Genomic Health to align with industry standards and best practices in carbon emissions management, particularly as climate commitments become increasingly critical for stakeholders.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 161,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 3,540,000 | 0,000,000 | 000,000 | 0,000,000 | 0,000,000 |
How Carbon Intensive is Genomic Health, Inc.'s Industry?
How Carbon Intensive is Genomic Health, Inc.'s Location?
Genomic Health, Inc.'s Scope 3 Categories Breakdown
Genomic Health, Inc.'s Scope 3 emissions, which decreased by 19% last year and increased by approximately 96% since 2019, demonstrating supply chain emissions tracking. A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 36% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Genomic Health, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genomic Health, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
